The Immune Response to SARS-CoV-2 Vaccine in a Cohort of Family Pediatricians from Southern Italy.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
23 May 2023
Historique:
received: 14 04 2023
revised: 18 05 2023
accepted: 19 05 2023
medline: 12 6 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: epublish

Résumé

In Italy, from January 2021, the Ministry of Health indicated a vaccination plan against COVID for frail patients and physicians based on a three-dose scheme. However, conflicting results have been reported on which biomarkers permit immunization assessment. We used several laboratory approaches (i.e., antibodies serum levels, flow cytometry analysis, and cytokines release by stimulated cells) to investigate the immune response in a cohort of 53 family pediatricians (FPs) at different times after the vaccine. We observed that the BNT162b2-mRNA vaccine induced a significant increase of specific antibodies after the third (booster) dose; however, the antibody titer was not predictive of the risk of developing the infection in the six months following the booster dose. The antigen stimulation of PBMC cells from subjects vaccinated with the third booster jab induced the increase of the activated T cells (i.e., CD4

Identifiants

pubmed: 37296568
pii: cells12111447
doi: 10.3390/cells12111447
pmc: PMC10252549
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
BNT162 Vaccine 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Italian Ministry of University and Research
ID : PRIN 2020, code 20209TB4AX
Organisme : University of Naples Federico II
ID : 2020 FRA LINEA B
Organisme : Regione Campania
ID : POR Campania FESR2014/2020 O.S. 1.3 AZ. 1.3.1 AVVISO DGR 504 del 10/11/2021 - CUP B63C22001270002
Organisme : Regione Campania
ID : CEINGE TASK-FORCE-2022 COVID19 CUP n. D63C22000570002
Organisme : Regione Campania
ID : POR Campania FESR 2014/2020, code SURF 21058BP000000020 CUP B63C22001210007

Références

Viruses. 2022 Nov 17;14(11):
pubmed: 36423150
Cell Rep Med. 2022 Aug 16;3(8):100716
pubmed: 35952669
Sci Immunol. 2021 Dec 24;6(66):eabl5344
pubmed: 34726470
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
J Med Virol. 2021 Jan;93(1):375-382
pubmed: 32579268
Front Immunol. 2022 Jun 01;13:859019
pubmed: 35720318
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Commun. 2022 Sep 21;13(1):5422
pubmed: 36130936
Geroscience. 2021 Oct;43(5):2321-2331
pubmed: 34633612
Transl Med Commun. 2022;7(1):22
pubmed: 36093039
Clin Infect Dis. 2021 Nov 2;73(9):e3130-e3132
pubmed: 33035306
Cell. 2022 Mar 17;185(6):1041-1051.e6
pubmed: 35202566
J Med Virol. 2022 May;94(5):1825-1832
pubmed: 35023191
Cell Rep Med. 2020 Sep 22;1(6):100092
pubmed: 32904468
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Vaccines (Basel). 2022 Mar 14;10(3):
pubmed: 35335079
Lancet. 2022 Apr 23;399(10335):1618-1624
pubmed: 35397851
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
Front Immunol. 2022 Apr 29;13:877101
pubmed: 35572518
N Engl J Med. 2022 Oct 6;387(14):1333-1336
pubmed: 36103621
Clin Transl Immunology. 2022 Oct 14;11(10):e1423
pubmed: 36254196
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
J Viral Hepat. 2011 Jul;18(7):e341-9
pubmed: 21692946
Front Immunol. 2022 Jul 26;13:944713
pubmed: 35990661
Immunity. 2023 Apr 11;56(4):864-878.e4
pubmed: 36996809
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33464307
Front Public Health. 2021 Jun 15;9:664108
pubmed: 34211953
Microorganisms. 2022 Nov 16;10(11):
pubmed: 36422345
Cell Rep Med. 2022 Jan 19;3(2):100520
pubmed: 35233545
Immunology. 2021 Jan;162(1):30-43
pubmed: 32935333
Clin Transl Immunology. 2022 Jan 11;11(1):e1360
pubmed: 35035955
Front Pediatr. 2021 Jul 28;9:697390
pubmed: 34395341
Front Immunol. 2022 Oct 03;13:985433
pubmed: 36263058
J Clin Med. 2022 Jul 25;11(15):
pubmed: 35893398
Vaccines (Basel). 2022 Apr 28;10(5):
pubmed: 35632450
Lancet. 2022 Jun 25;399(10344):2351-2380
pubmed: 35405084
Semin Immunol. 2021 Jun;55:101505
pubmed: 34711489
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33945513
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Inflamm Regen. 2022 Nov 29;42(1):51
pubmed: 36447270
Front Immunol. 2022 Apr 22;13:869990
pubmed: 35529867

Auteurs

Paolo Cortese (P)

Federazione Italiana Medici Pediatri (FIMP), 80142 Naples, Italy.

Felice Amato (F)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
CEINGE Biotecnologie Avanzate Franco Salvatore, Scarl, 80131 Naples, Italy.

Antonio Davino (A)

Federazione Italiana Medici Pediatri (FIMP), 80142 Naples, Italy.

Raffaella De Franchis (R)

Federazione Italiana Medici Pediatri (FIMP), 80142 Naples, Italy.

Speranza Esposito (S)

CEINGE Biotecnologie Avanzate Franco Salvatore, Scarl, 80131 Naples, Italy.

Immacolata Zollo (I)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
CEINGE Biotecnologie Avanzate Franco Salvatore, Scarl, 80131 Naples, Italy.

Marina Di Domenico (M)

Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80138 Naples, Italy.

Egle Solito (E)

Centre for Translational Medicine and Therapeutics William Harvey Research Institute, Queen Mary Univesity, London E1 4NS, UK.

Federica Zarrilli (F)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
CEINGE Biotecnologie Avanzate Franco Salvatore, Scarl, 80131 Naples, Italy.

Laura Gentile (L)

CEINGE Biotecnologie Avanzate Franco Salvatore, Scarl, 80131 Naples, Italy.

Gustavo Cernera (G)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
CEINGE Biotecnologie Avanzate Franco Salvatore, Scarl, 80131 Naples, Italy.

Giuseppe Castaldo (G)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
CEINGE Biotecnologie Avanzate Franco Salvatore, Scarl, 80131 Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH